PubMed Health⌕ Search

PubMed · 15533419

Compositional changes in cement-stabilized waste during leach tests--comparison of SEM/EDX data with predictions from geochemical speciation modeling.

Abstract

Cement-based stabilization/solidification (s/s) is a widely used treatment process for hazardous wastes containing toxic metals. The treated waste consists of a complex mixture of several solid phases produced by cement hydration reactions. Understanding and predicting the effects of leaching on these individual phases is essential for assessing the long-term immobilization of metal contaminants in s/s waste exposed to rain and groundwater. In this paper, particles of crushed Portland cement doped with copper, lead, and zinc nitrates were leached with nitric acid solutions maintained at constant pH in the range pH 4-7. Changes in solid composition at the microscopic scale were measured by scanning electron microscopy and energy dispersive X-ray spectrometry (SEM/EDX). The geochemical equilibrium model SOLTEQ-B, which accounts for the incongruent solubility behavior of calcium silicate hydrate, was used to simulate the compositional changes in the hydration gel for increasing extents of leaching. Measured concentrations of calcium, silicon, and sulfur were successfully predicted at all extents of leaching. Aluminum, lead, and zinc concentrations were also in good agreement with model predictions, except in the remineralization zones that form when metals solubilized in the outer regions of the s/s waste particles diffuse toward the interior and reprecipitate at higher pH. Copper was less accurately modeled at high extents of leaching. Accounting for the incorporation of contaminant metals into the cement hydration gel (in opposition to assuming the presence of individual metal hydroxides) is crucial for successfully predicting contaminant metal concentrations in the hydration gel at low and intermediate extents of leaching.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Violaine Mijno, Lionel J J Catalan, François Martin, Jean-Claude Bollinger. 2004-12-15. Compositional changes in cement-stabilized waste during leach tests--comparison of SEM/EDX data with predictions from geochemical speciation modeling.. https://doi.org/10.1016/j.jcis.2004.08.025

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗